Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
Chimeric antigen receptor (CAR)-based therapy for the treatment of liver cancer represents a promising therapeutic strategy. Here the authors show that CD147-targeting CAR-NK or CAR-T can induce anti-tumor activity against hepatocellular carcinoma in vitro and in vivo.
Guardado en:
Autores principales: | Hsiang-chi Tseng, Wei Xiong, Saiaditya Badeti, Yan Yang, Minh Ma, Ting Liu, Carlos A. Ramos, Gianpietro Dotti, Luke Fritzky, Jie-gen Jiang, Qing Yi, James Guarrera, Wei-Xing Zong, Chen Liu, Dongfang Liu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d4aefc73f7c342c4befc39c05ef9b986 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Chimeric antigen receptor modified T-cells for cancer treatment
por: Xiao Han, et al.
Publicado: (2018) -
A TCR-based Chimeric Antigen Receptor
por: Even Walseng, et al.
Publicado: (2017) -
Hepatitis E virus capsid as a carrier of exogenous antigens for the development of chimeric virus-like particles
por: Tianyu Lu, et al.
Publicado: (2021) -
Acta No. 147
por: Banco Central de Chile
Publicado: (2019) -
Structure-based design of chimeric antigens for multivalent protein vaccines
por: S. Hollingshead, et al.
Publicado: (2018)